Nicox S.A.
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-09-04 07:30 |
Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps dow…
|
English | 174.7 KB | ||
| 2024-07-25 07:30 |
Nicox : Recrutement du dernier patient aux Etats- Unis dans l’étude clinique de…
|
French | 105.5 KB | ||
| 2024-07-25 07:30 |
Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of …
|
English | 116.5 KB | ||
| 2024-07-19 07:30 |
Nicox announces attendance at upcoming conferences
|
English | 99.9 KB | ||
| 2024-07-19 07:30 |
Nicox : Participation aux prochaines conférences
|
French | 97.9 KB | ||
| 2024-07-18 07:30 |
Nicox : Résumé financier du deuxième trimestre 2024
|
French | 129.2 KB | ||
| 2024-07-18 07:30 |
Nicox Provides Second Quarter 2024 Update
|
English | 124.6 KB | ||
| 2024-07-16 07:30 |
Nicox nomme le dirigeant biotech expérimenté Damian Marron Président du Conseil…
|
French | 110.6 KB | ||
| 2024-07-16 07:30 |
Nicox appoints experienced biotech leader Damian Marron as Chair of the Board a…
|
English | 120.4 KB | ||
| 2024-06-27 17:30 |
Nicox : Assemblée Générale Ordinaire 2024
|
French | 91.1 KB | ||
| 2024-06-27 17:30 |
Nicox: 2024 Ordinary Shareholder Meeting
|
English | 91.5 KB | ||
| 2024-06-19 07:30 |
Nicox annonce le succès de son augmentation de capital avec maintien du droit p…
|
French | 180.4 KB | ||
| 2024-06-03 07:30 |
Nombre de droits de vote au 31 mai 2024
|
French | 72.9 KB | ||
| 2024-06-03 07:30 |
Number of voting rights as of May 31, 2024
|
English | 80.5 KB | ||
| 2024-05-31 07:30 |
Nicox annonce l’organisation d’un webcast pour ses actionnaires le 6 juin 2024 …
|
French | 106.4 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
